A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 in patients with advanced triple-negative breast cancer (TNBC) who have progressed after prior therapy.

Trial Details

NCT ID
NCT07208149
Phase
PHASE1 / PHASE2
Sponsor
Shenzhen Majory Biotechnology Co., Ltd.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • MR001 Bispecific Antibody for Injection
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Patients with histologically or cytologically confirmed triple-negative breast cancer (TNBC).
  • Subjects with locally recurrent or metastatic advanced TNBC who have progressed after first-line or later-line therapy.
  • Presence of at least one measurable lesion according to RECIST V1.1 criteria.
  • ECOG Performance Status 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →